|
Servier
Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). The consolidated turnover for the 2018 financial year was €4.2 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 149 countries, achieving 82% of its sales outside France. The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide. The company's production sites produced 853 million drug boxes in 2013. The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe. Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In 2018, Servier f ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Agomelatine
Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but less discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants. Common side effects include weight gain, fatigue, liver problems, nausea, headaches, and anxiety. Due to potential liver problems ongoing blood tests are recommended. Its use is not recommended in people with dementia or over the age of 75. There is tentative evidence that it may have fewer side effects than some other antidepressants. It acts by blocking certain serotonin receptors and activating melatonin receptors. Agomelatine was approved for medical use in Europe in 2009 and Australia in 2010. Its use is not approved in the United States and e ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Jacques Servier
Jacques Servier (9 February 1922 – 16 April 2014) was a French doctor and businessman. He was the founder and president of Laboratoires Servier, a pharmaceutical company. Biography Founder of the pharmaceutical group Servier in 1954, he had a fortune estimated at US$7.7 billion. The group led by him, Servier, had been convicted several times to pay damages for Mediator, trade name of benfluorex. There was a class action also for Isoméride, trade name of dexfenfluramine. There are also active discussions and trial around benfluorex. Decorations *Legion of Honour **Knight (1976) **Officer (1 December 1987; by Minister of Social Affairs and Employment Philippe Séguin) **Commander (31 December 1992; by Minister for Foreign Trade Dominique Strauss-Kahn) **Grand Officer (25 March 2002; by President Jacques Chirac) **Grand Cross (31 December 2008; by President Nicolas Sarkozy) * National Order of Merit **Officer (1981) **Commander (21 May 1985; by President François Mitterrand) ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Tianeptine
Tianeptine, sold under the brand names Stablon and Coaxil among others, is an atypical antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome. Tianeptine has antidepressant and anxiolytic effects with a relative lack of sedative, anticholinergic, and cardiovascular side effects. It has been found to act as an atypical agonist of the μ-opioid receptor with clinically negligible effects on the δ- and κ-opioid receptors. Tianeptine was discovered and patented by the French Society of Medical Research in the 1960s. Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in a number of other European countries under the trade name Coaxil as well as in Asia (including Singapore) and Latin America as Stablon and Tatinol but it is not available in Australia, Canada, New Zealand, or the United Kingdom. M ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Benfluorex
Benfluorex, sold under the brand name Mediator, is an anorectic and hypolipidemic agent that is structurally related to fenfluramine (a substituted amphetamine). It may improve glycemic control and decrease insulin resistance in people with poorly controlled type-2 diabetes. It was on the market between 1976 and 2009, and is thought to have caused between 500 and 2,000 deaths. It was patented and manufactured by the French pharmaceutical company Servier. However, Servier is suspected of having marketed benfluorex at odds with the drug's medical properties. On March 29, 2021, a French court fined Servier €2.7m (£2.3m) after finding it guilty of deception and manslaughter. Drug withdrawn On 18 December 2009, the European Medicines Agency recommended the withdrawal of all medicines containing benfluorex in the European Union, because their risks, particularly the risk of heart valve disease (fenfluramine-like cardiovascular side effects), are greater than their benefits. Thus F ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Strontium Ranelate
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA). On 13 May 2013, Servier released a Direct Healthcare Professional Communication which stated that new restrictions for the use of strontium ranelate are now in place, as randomised trials have shown an increased risk of myocardial infarction. Servier states that the use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture. The European Pharmacovigilance Risk Assessment Committee (PRAC) recommended restriction in the use of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which included data showin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Perindopril
Perindopril is a medication used to treat high blood pressure, heart failure, or stable coronary artery disease. As a long-acting ACE inhibitor, it works by relaxing blood vessels and decreasing blood volume. As a prodrug, perindopril is hydrolyzed in the liver to its active metabolite, perindoprilat. It was patented in 1980 and approved for medical use in 1988. Perindopril is taken in the form of perindopril arginine (trade names include Coversyl, Coversum) or perindopril erbumine (Aceon). Both forms are therapeutically equivalent and interchangeable, but the dose prescribed to achieve the same effect differs between the two forms. It is also often combined with another medication, sometimes in the same tablet (see #Combinations below). Medical uses Perindopril shares the indications of ACE inhibitors as a class, including essential hypertension, stable coronary artery disease (reduction of risk of cardiac events in patients with a history of myocardial infarctio ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ivabradine
Ivabradine, sold under the brand name Procoralan among others, is a medication, which is a funny current (I''f'') inhibitor, used for the symptomatic management of heart-related chest pain and heart failure. Patients who qualify for use of Ivabradine for coronary heart failure are patients who have symptomatic heart failure, with reduced ejection volume, and heart rate at least 70 bpm, and the condition not able to be fully managed by beta blockers. Ivabradine acts by allowing negative chronotropy in the sinoatrial structure thus reducing the heart rate via specific inhibition of the pacemaker current, a mechanism different from that of beta blockers and calcium channel blockers, two commonly prescribed antianginal classes of cardiac pharmaceuticals. Ivabradine has no apparent inotropic properties and may be a cardiotonic agent. Medical uses It is used for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm who cannot take beta blocke ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Trimetazidine
Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug for angina pectoris (chest pain associated with blood flow to the heart) sold under many brand names. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves myocardial glucose utilization through inhibition of fatty acid metabolism. Medical uses Trimetazidine is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness. It is taken twice a day. In 2012, the European Medicines Agency (EMA) finished a review of benefits and risks of trimetazidine and recommended restricting use of trimetazidine-containing medicines to just as an additional treatment of angina pectoris in cases of inadequate control by or intolerance to first-line antia ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Osteoporosis
Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to bone fragility, and consequent increase in fracture risk. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the vertebrae in the spine, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. After the broken bone heals, the person may have chronic pain and a decreased ability to carry out normal activities. Osteoporosis may be due to lower-than-normal maximum bone mass and greater-than-normal bone loss. Bone loss increases after the menopause due to lower levels of estrogen, and after ' andropause' due to lower levels of testosterone. Osteoporosis may also occur due to a number of diseases or treatments, including alcoholism, anorexia, hyperthyroidism, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Indapamide
Indapamide is a thiazide-like diuretic drug used in the treatment of hypertension, as well as decompensated heart failure. Combination preparations with perindopril (an ACE inhibitor antihypertensive) are available. The thiazide-like diuretics (indapamide and chlorthalidone) reduce risk of major cardiovascular events and heart failure in hypertensive patients compared with hydrochlorothiazide with a comparable incidence of adverse events. Both thiazide diuretics and thiazide-like diuretics are effective in reducing risk of stroke. Both drug classes appear to have comparable rates of adverse effects as other antihypertensives such as angiotensin II receptor blockers and dihydropyridine calcium channel blockers and lesser prevalence of side-effects when compared to ACE-inhibitors and non-dihydropyridine calcium channel blockers. It was patented in 1968 and approved for medical use in 1977. It is on the World Health Organization's List of Essential Medicines. Medical uses Its in ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Gliclazide
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. It is used when dietary changes, exercise, and weight loss are not enough. It is taken by mouth. Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems. Use by those with significant kidney problems or liver problems or who are pregnant is not recommended. Gliclazide is in the sulfonylurea family of medications. It works mostly by increasing the release of insulin. Gliclazide was patented in 1966 and approved for medical use in 1972. It is on the World Health Organization's List of Essential Medicines. It is not available for sale in the United States. Medical uses Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non- ketosis prone, type 2 diabetes. It is used when diabetes cannot be controlled by proper dietary management and exercise ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Orléans
Orléans (;"Orleans" (US) and , ) is a city in north-central France, about 120 kilometres (74 miles) southwest of Paris. It is the prefecture of the Departments of France, department of Loiret and of the Regions of France, region of Centre-Val de Loire. Orléans is located on the river Loire nestled in the heart of the Loire Valley, classified as a Loire Valley, World Heritage Site, where the river curves south towards the Massif Central. In 2019, the city had 116,269 inhabitants within its municipal boundaries. Orléans is the center of Orléans Métropole that has a population of 288,229. The larger Functional area (France), metropolitan area has a population of 451,373, the 20th largest in France. The city owes its ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
.jpg "Click for more on -> Orléans")